Azetukalner not checked
Xenon Pharmaceuticals Inc. · XEN1101
FollowEvery change as it happens, and a Monday email
Trials
8 active
11 in total · 9 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.”In the company’s words, NCT06922110 on ClinicalTrials.gov
- Tested for
- Major Depressive Disorder (2 trials), Bipolar Disorder (2 trials), Bipolar Depression (2 trials), Bipolar I Disorder (2 trials), Bipolar II Disorder (2 trials), Focal Epilepsy (2 trials), Primary Generalized Tonic-Clonic Seizures, Focal Onset Seizures and 1 more
- Main trialPhase 3
- “X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).”In the company’s words, NCT06922110 on ClinicalTrials.gov
- Other names
- XEN1101
Other drugs for Major Depressive Disorder
- SeltorexantJanssen Research & Development, LLC · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
- DT120Definium Therapeutics US, Inc. · Phase 3
Coming up7
- Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- May 2027Phase 3 trial completes · ClinicalTrials.gov
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2029Phase 3 trial completes · ClinicalTrials.gov
- Apr 2033Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 18 NovStatus changed: Active, not recruiting to Terminated · ClinicalTrials.gov NCT06775379
- 18 NovCompletion date moved: 2026-10 to 2026-10-28 · ClinicalTrials.gov NCT06775379
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Jan 2027 | An Open-Label Study of Azetukalner in Major Depressive Disorder | |
| Phase 3Recruiting | Apr 2027 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | |
| Phase 3Active, not recruiting | May 2027 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | |
| Phase 3Recruiting | Jan 2028 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | |
| Phase 3Active, not recruiting | Jun 2028 | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | |
| Phase 3Active, not recruiting | Jun 2029 | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | |
| Phase 3Enrolling by invitation | Apr 2033 | An Open-label Study of XEN1101 in Epilepsy | |
| Phase 2Active, not recruiting | 2 Sep 2021 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | |
| Phase 3Completed | 12 Jan 2026 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | |
| Phase 3Terminated | 28 Oct 2026 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | |
| Phase 2Completed | 18 Sep 2023 | A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026